preclinical_heavy
Preclinical evidence exceeds central human evidence. Interpret translational relevance cautiously.
supportedtophigh inflation risk
Candida albicans
inflammatory bowel disease
Candida albicans has meaningful literature visibility in inflammatory bowel disease, but the current evidence mix suggests a substantial risk of overclaiming.
Candida albicans shows a moderate evidence base in inflammatory bowel disease, with multiple central papers and additional supporting literature.
candida_albicans
Credibility score
69
Human translation
2/5
Reproducibility
5/5
Novelty
1/5
Actionability
3/5
Credibility 69Human translation 2/5Reproducibility 5/5Novelty 1/5Actionability 3/5
Why this scores the way it does
- moderate central evidence base
- dense review literature
- substantial preclinical support
Main caveats
- preclinical evidence outweighs human evidence
- retrieval noise or disease-specificity issues may remain
Internal review flags
2 flagsreview_heavy
Review literature is very dense relative to primary central evidence.
Primary central evidence
14 papersEnterococcus faecalis induces inflammatory bowel disease in interleukin-10 knockout mice.
2002The American journal of pathology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Fungal Signature in the Gut Microbiota of Pediatric Patients With Inflammatory Bowel Disease.
2015Inflammatory bowel diseases
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Fungal microbiota dysbiosis in IBD.
2017Gut
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Characterization of fungal dysbiosis in Japanese patients with inflammatory bowel disease.
2019Journal of gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Immune regulation by fungal strain diversity in inflammatory bowel disease.
2022Nature
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
The gut fungal and bacterial microbiota in pediatric patients with inflammatory bowel disease introduced to treatment with anti-tumor necrosis factor-α.
2022Scientific reports
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
The ileal fungal microbiota is altered in Crohn's disease and is associated with the disease course.
2022Frontiers in medicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Fungal Microbiota Composition in Inflammatory Bowel Disease Patients: Characterization in Different Phenotypes and Correlation With Clinical Activity and Disease Course.
2024Inflammatory bowel diseases
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Evaluation of Bacterial and Fungal Biomarkers for Differentiation and Prognosis of Patients with Inflammatory Bowel Disease.
2023Microorganisms
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Typing of feces-derived Candida albicans strains using a novel seven-locus microsatellite panel reveals associations with yeast phenotype in individuals with inflammatory bowel disease.
2025Pathogens and disease
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Adverse Events and Immune Response in Psoriasis Patients Receiving Interleukin-17 Inhibitors.
2025Acta dermato-venereologica
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Mycobiota dynamics in inflammatory bowel disease: Fungal biomarkers and Clostridioides difficile co-infection.
2025Microbial pathogenesis
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
A gut-secreted histidine methyltransferase enforces cross-kingdom catalytic antifungal defense.
2026Cell host & microbe
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Fecal Mycobiota in Patients with Inflammatory Bowel Diseases and Extraintestinal Manifestations.
2024Gut microbes reports
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Preclinical supporting evidence
16 papersPhagocytosis, killing, lymphocyte-mediated antibacterial activity, serum autoantibodies, and plasma endotoxins in inflammatory bowel disease.
2000The American journal of gastroenterology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Human colonic mucus is a reservoir for antimicrobial peptides.
2013Journal of Crohn's & colitis
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Microorganisms linked to inflammatory bowel disease-associated dysbiosis differentially impact host physiology in gnotobiotic mice.
2016The ISME journal
Disease-relevant preclinical or model-based paper useful as supporting evidence.
CX3CR1+ mononuclear phagocytes control immunity to intestinal fungi.
2018Science (New York, N.Y.)
Disease-relevant preclinical or model-based paper useful as supporting evidence.
H89 Treatment Reduces Intestinal Inflammation and Candida albicans Overgrowth in Mice.
2020Microorganisms
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Vaginal microbiota in pregnant women with inflammatory rheumatic and inflammatory bowel disease: A matched case-control study.
2021Mycoses
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Absence of Oral Opportunistic Infections in Patients with Inflammatory Bowel Disease Receiving Anti-TNF-α and Anti-Integrin-α4β7 Therapy.
2022Dentistry journal
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Crohn's Disease Patients Uniquely Contain Inflammatory Responses to Flagellin in a CD4 Effector Memory Subset.
2022Inflammatory bowel diseases
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Kruppel-like factor 2+ CD4 T cells avert microbiota-induced intestinal inflammation.
2023Cell reports
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Chemoprofiling and antimicrobial activity of medicinal herbs used in the treatment of inflammatory bowel disease.
2023Cellular and molecular biology (Noisy-le-Grand, France)
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials.
2024Dermatology and therapy
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Candida tropicalis Affects Candida albicans Virulence by Limiting Its Capacity to Adhere to the Host Intestinal Surface, Leading to Decreased Susceptibility to Colitis in Mice.
2024Journal of fungi (Basel, Switzerland)
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Disability, Physical Activity, and Their Correlates in Patients With Inflammatory Bowel Disease: A Portuguese Cross-Sectional Survey.
2024Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Candida tropicalis-derived vitamin B3 exerts protective effects against intestinal inflammation by promoting IL-17A/IL-22-dependent epithelial barrier function.
2024Gut microbes
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studies.
2025Rheumatology (Oxford, England)
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Synergistic exacerbation of oral mucositis caused by IL-23 deficiency and oral Candida albicans exposure.
2025mBio
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Review supporting evidence
35 papersIBD serological panels: facts and perspectives.
2007Inflammatory bowel diseases
Relevant review or meta-analysis for the signal-disease area.
Pathogenic agents in inflammatory bowel diseases.
2008Current opinion in gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Therapy- and non-therapy-dependent infectious complications in inflammatory bowel disease.
2009Digestive diseases (Basel, Switzerland)
Relevant review or meta-analysis for the signal-disease area.
Inflammation and gastrointestinal Candida colonization.
2011Current opinion in microbiology
Relevant review or meta-analysis for the signal-disease area.
An immunological link between Candida albicans colonization and Crohn's disease.
2015Critical reviews in microbiology
Relevant review or meta-analysis for the signal-disease area.
Digestive tract mycobiota: a source of infection.
2015Medecine et maladies infectieuses
Relevant review or meta-analysis for the signal-disease area.
Nocardia infections among immunomodulated inflammatory bowel disease patients: A review.
2015World journal of gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Proceedings of the 3rd IPLeiria's International Health Congress : Leiria, Portugal. 6-7 May 2016.
2016BMC health services research
Relevant review or meta-analysis for the signal-disease area.
Clinical Trial and Registry Data.
2018Current problems in dermatology
Relevant review or meta-analysis for the signal-disease area.
Fungal infections in patients with inflammatory bowel disease: A systematic review.
2018Mycoses
Relevant review or meta-analysis for the signal-disease area.
Guselkumab for the Treatment of Psoriasis.
2018BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Relevant review or meta-analysis for the signal-disease area.
The Gut Microbiota in the Pathogenesis and Therapeutics of Inflammatory Bowel Disease.
2018Frontiers in microbiology
Relevant review or meta-analysis for the signal-disease area.
[Microbiota and inflammatory bowel disease: an update.].
2018Recenti progressi in medicina
Relevant review or meta-analysis for the signal-disease area.
Review article: fungal alterations in inflammatory bowel diseases.
2019Alimentary pharmacology & therapeutics
Relevant review or meta-analysis for the signal-disease area.
The daily impact of COVID-19 in gastroenterology.
2020United European gastroenterology journal
Relevant review or meta-analysis for the signal-disease area.
Fungi of the human gut microbiota: Roles and significance.
2021International journal of medical microbiology : IJMM
Relevant review or meta-analysis for the signal-disease area.
Fungal Colonization and Infections-Interactions with Other Human Diseases.
2022Pathogens (Basel, Switzerland)
Relevant review or meta-analysis for the signal-disease area.
Fungal microbiome in inflammatory bowel disease: a critical assessment.
2022The Journal of clinical investigation
Relevant review or meta-analysis for the signal-disease area.
Immunosurveillance of Candida albicans commensalism by the adaptive immune system.
2022Mucosal immunology
Relevant review or meta-analysis for the signal-disease area.
Mycobiome and Inflammatory Bowel Disease: Role in Disease Pathogenesis, Current Approaches and Novel Nutritional-based Therapies.
2023Inflammatory bowel diseases
Relevant review or meta-analysis for the signal-disease area.
Alteration of the Gut Microbiome in Inflammatory Bowel Disease.
2023Digestion
Relevant review or meta-analysis for the signal-disease area.
Friendly fungi: symbiosis with commensal Candida albicans.
2022Trends in immunology
Relevant review or meta-analysis for the signal-disease area.
Insight into the Relationship between Oral Microbiota and the Inflammatory Bowel Disease.
2022Microorganisms
Relevant review or meta-analysis for the signal-disease area.
Fungal feelings in the irritable bowel syndrome: the intestinal mycobiome and abdominal pain.
2023Gut microbes
Relevant review or meta-analysis for the signal-disease area.
Immunoglobulins at the interface of the gut mycobiota and anti-fungal immunity.
2023Seminars in immunology
Relevant review or meta-analysis for the signal-disease area.
Candida spp. in Human Intestinal Health and Disease: More than a Gut Feeling.
2023Mycopathologia
Relevant review or meta-analysis for the signal-disease area.
Mucosal Immunity to Gut Fungi in Health and Inflammatory Bowel Disease.
2023Journal of fungi (Basel, Switzerland)
Relevant review or meta-analysis for the signal-disease area.
From ASCA breakthrough in Crohn's disease and Candida albicans research to thirty years of investigations about their meaning in human health.
2024Autoimmunity reviews
Relevant review or meta-analysis for the signal-disease area.
A comprehensive guide to assess gut mycobiome and its role in pathogenesis and treatment of inflammatory bowel disease.
2024Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Bacteria-derived short-chain fatty acids as potential regulators of fungal commensalism and pathogenesis.
2024Trends in microbiology
Relevant review or meta-analysis for the signal-disease area.
Role of Candida species in pathogenesis, immune regulation, and prognostic tools for managing ulcerative colitis and Crohn's disease.
2024World journal of gastroenterology
Relevant review or meta-analysis for the signal-disease area.
The gastrointestinal mycobiome in inflammation and cancer: unraveling fungal dysbiosis, pathogenesis, and therapeutic potential.
2025Medical oncology (Northwood, London, England)
Relevant review or meta-analysis for the signal-disease area.
Fucoidan as a therapeutic agent for ulcerative colitis: mechanisms of action and modulation of the gut microbiota.
2025Frontiers in cellular and infection microbiology
Relevant review or meta-analysis for the signal-disease area.
Gut Mycobiome in Inflammatory Bowel Disease: A Systematic Review of Case-Control Studies.
2025Inflammatory bowel diseases
Relevant review or meta-analysis for the signal-disease area.
Neglected kingdoms: the gut virome, mycobiome and their role in inflammatory bowel disease.
2026Gut microbes
Relevant review or meta-analysis for the signal-disease area.